BeOne Medicines: Pay

BeOne Medicines paid its 4 named executives $41.8M in total in FY2025 (Dec).

Pay$100 in the stock at the end of FY20 → $71
CEO pay is from each proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Pay of each named executive

John V. OylerCo-Founder, Chairman and Chief Executive Officer
FY2024 (Dec)
FY2023 (Dec)
FY2022 (Dec)Not disclosed
FY2021 (Dec)Not disclosed
4 years
Dr. Lai WangPresident, Global Head of Research and Development
FY2025 (Dec)
FY2024 (Dec)
FY2023 (Dec)
FY2022 (Dec)Not disclosed
FY2021 (Dec)Not disclosed
5 years
Dr. Xiaobin WuPresident and Chief Operating Officer
FY2025 (Dec)
FY2024 (Dec)
FY2023 (Dec)
FY2022 (Dec)Not disclosed
FY2021 (Dec)Not disclosed
5 years
Aaron RosenbergChief Financial Officer
FY2025 (Dec)
FY2024 (Dec)Not disclosed
2 years
Chan LeeSenior Vice President, General Counsel and Corporate Secretary
FY2025 (Dec)
FY2024 (Dec)
FY2023 (Dec)
3 years

CEO pay against the pay peers

In FY2025 (Dec), the median CEO pay of the 9 peers with pay on file was $19.9M. CEO pay of BeOne Medicines for that year is not on file.

  1. 1Exelixis
  2. 2Incyte
  3. 3Gilead Sciences
  4. 4Biomarin Pharmaceutical
  5. 5Moderna
  6. 6United Therapeutics
  7. 7Alnylam Pharmaceuticals
  8. 8Regeneron Pharmaceuticals
  9. 9Neurocrine Biosciences
  10. 10BeOne MedicinesNot disclosed
  11. 11BiogenNot disclosed
  12. 12Jazz PharmaceuticalsNot disclosed
  13. 13Sarepta Therapeutics, Inc.Not disclosed
  14. 14Vertex Pharmaceuticals Inc.Not disclosed

Pay of each named executive comes from the Summary Compensation Table of each proxy statement. Realized pay adds the value of options used and stock that vested. CEO pay of each peer comes from its own Pay versus Performance table.